NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $0.50 0.00 (-0.70%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends About Bolt Biotherapeutics Stock (NASDAQ:BOLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bolt Biotherapeutics alerts:Sign Up Key Stats Today's Range$0.49▼$0.5250-Day Range$0.50▼$0.6852-Week Range$0.49▼$1.56Volume69,985 shsAverage Volume166,667 shsMarket Capitalization$19.14 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingHold Company OverviewBolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Read More… Bolt Biotherapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks46th Percentile Overall ScoreBOLT MarketRank™: Bolt Biotherapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 567th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingBolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Bolt Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.61) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.47% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 19.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth.Read more about Bolt Biotherapeutics' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.47% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 19.23%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added Bolt Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.90% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bolt Biotherapeutics' insider trading history. Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLT Stock News HeadlinesBolt Biotherapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 15, 2024 | finance.yahoo.comBolt Biotherapeutics Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comForced out of retirement by these trades You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changedDecember 23, 2024 | DTI (Ad)Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer LookNovember 15, 2024 | markets.businessinsider.comBolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue EstimatesNovember 13, 2024 | msn.comBolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | markets.businessinsider.comBolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual MeetingNovember 7, 2024 | globenewswire.comBy popular demand, Epiphone brings back the Mike Dirnt and Gene Simmons-approved Grabber BassSeptember 27, 2024 | msn.comSee More Headlines BOLT Stock Analysis - Frequently Asked Questions How have BOLT shares performed this year? Bolt Biotherapeutics' stock was trading at $1.12 at the start of the year. Since then, BOLT stock has decreased by 55.4% and is now trading at $0.50. View the best growth stocks for 2024 here. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.04. The company had revenue of $1.14 million for the quarter, compared to analysts' expectations of $1.02 million. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 69.46% and a negative net margin of 665.56%. When did Bolt Biotherapeutics IPO? Bolt Biotherapeutics (BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO. Who are Bolt Biotherapeutics' major shareholders? Top institutional investors of Bolt Biotherapeutics include Geode Capital Management LLC (0.92%) and FMR LLC (0.30%). Insiders that own company stock include Holdings A/S Novo, Edgar Engleman, Vivo Capital Viii, Llc and William P Quinn. View institutional ownership trends. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV). Company Calendar Last Earnings11/12/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLT CUSIP09769810 CIK354655 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$8.00 Low Stock Price Target$1.00 Potential Upside/Downside+600.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,200,000.00 Net Margins-665.56% Pretax Margin-665.56% Return on Equity-69.46% Return on Assets-48.55% Debt Debt-to-Equity Ratio0.21 Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual Sales$9.78 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book0.17Miscellaneous Outstanding Shares38,273,000Free Float26,447,000Market Cap$19.14 million OptionableNot Optionable Beta0.93 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:BOLT) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.